IPRs in biobanking- risks and opportunities for translational research

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

IPRs in biobanking- risks and opportunities for translational research. / Minssen, Timo; Verlinden, Michiel; Huys, Isabelle .

In: Intellectual Property Quarterly, Vol. 2015, No. 2, 06.2015, p. 106-129.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Minssen, T, Verlinden, M & Huys, I 2015, 'IPRs in biobanking- risks and opportunities for translational research', Intellectual Property Quarterly, vol. 2015, no. 2, pp. 106-129.

APA

Minssen, T., Verlinden, M., & Huys, I. (2015). IPRs in biobanking- risks and opportunities for translational research. Intellectual Property Quarterly, 2015(2), 106-129.

Vancouver

Minssen T, Verlinden M, Huys I. IPRs in biobanking- risks and opportunities for translational research. Intellectual Property Quarterly. 2015 Jun;2015(2):106-129.

Author

Minssen, Timo ; Verlinden, Michiel ; Huys, Isabelle . / IPRs in biobanking- risks and opportunities for translational research. In: Intellectual Property Quarterly. 2015 ; Vol. 2015, No. 2. pp. 106-129.

Bibtex

@article{cd350ab98ba14fcfadc2383b0ff6e609,
title = "IPRs in biobanking- risks and opportunities for translational research",
abstract = "The gradual shift from traditional closed innovation systems to more “open” and “transparent” innovation models, rapid technological advances and bio-pharmaceutical innovation gaps have highlighted the importance of an effective governance and use of biobanks. This raises important legal questions such as how to deal with intellectual property rights (‘IPRs’) that might arise out of the collection and use of samples and data in research. Only a few projects highlighted the opportunities and potential benefits of user-generated solutions and proper governance of IPRs. This paper aims to provide an overview and analysis of the most relevant IPRs in biobanking and to discuss the challenges and opportunities associated with an effective use of biobanks in translational research and innovation. Section 1 specifies challenges in finding a balance between an open and a close collaboration model. Section 2 will analyze and discuss potential strategies and options to stimulate the exchange of HBM, data and research results. It will also look into the question of how to address, govern and manage IPRs directed to biobank material and data. This will ultimately allow us to draw conclusions in section 3.",
keywords = "Faculty of Law, Biobank, IPRs, biotechnology, trade secrets",
author = "Timo Minssen and Michiel Verlinden and Isabelle Huys",
year = "2015",
month = "6",
language = "English",
volume = "2015",
pages = "106--129",
journal = "Intellectual Property Quarterly",
issn = "1364-906X",
publisher = "Sweet & Maxwell Ltd.",
number = "2",

}

RIS

TY - JOUR

T1 - IPRs in biobanking- risks and opportunities for translational research

AU - Minssen, Timo

AU - Verlinden, Michiel

AU - Huys, Isabelle

PY - 2015/6

Y1 - 2015/6

N2 - The gradual shift from traditional closed innovation systems to more “open” and “transparent” innovation models, rapid technological advances and bio-pharmaceutical innovation gaps have highlighted the importance of an effective governance and use of biobanks. This raises important legal questions such as how to deal with intellectual property rights (‘IPRs’) that might arise out of the collection and use of samples and data in research. Only a few projects highlighted the opportunities and potential benefits of user-generated solutions and proper governance of IPRs. This paper aims to provide an overview and analysis of the most relevant IPRs in biobanking and to discuss the challenges and opportunities associated with an effective use of biobanks in translational research and innovation. Section 1 specifies challenges in finding a balance between an open and a close collaboration model. Section 2 will analyze and discuss potential strategies and options to stimulate the exchange of HBM, data and research results. It will also look into the question of how to address, govern and manage IPRs directed to biobank material and data. This will ultimately allow us to draw conclusions in section 3.

AB - The gradual shift from traditional closed innovation systems to more “open” and “transparent” innovation models, rapid technological advances and bio-pharmaceutical innovation gaps have highlighted the importance of an effective governance and use of biobanks. This raises important legal questions such as how to deal with intellectual property rights (‘IPRs’) that might arise out of the collection and use of samples and data in research. Only a few projects highlighted the opportunities and potential benefits of user-generated solutions and proper governance of IPRs. This paper aims to provide an overview and analysis of the most relevant IPRs in biobanking and to discuss the challenges and opportunities associated with an effective use of biobanks in translational research and innovation. Section 1 specifies challenges in finding a balance between an open and a close collaboration model. Section 2 will analyze and discuss potential strategies and options to stimulate the exchange of HBM, data and research results. It will also look into the question of how to address, govern and manage IPRs directed to biobank material and data. This will ultimately allow us to draw conclusions in section 3.

KW - Faculty of Law

KW - Biobank, IPRs, biotechnology, trade secrets

M3 - Journal article

VL - 2015

SP - 106

EP - 129

JO - Intellectual Property Quarterly

JF - Intellectual Property Quarterly

SN - 1364-906X

IS - 2

ER -

ID: 128930973